Pediatric diffuse intrinsic pontine gliomas- a prospective observational study from a tertiary care neurosurgical center
- 27 December 2024
- journal article
- research article
- Published by Springer Nature in Child's Nervous System
- Vol. 41 (1) , 1-13
Abstract
Introduction Diffuse intrinsic pontine glioma (DIPG) in children comprises 80% of brainstem gliomas. In 2021, 5th edition of WHO CNS tumor classification defined H3K27M altered diffuse midline gliomas (DMGs) which replaced this entity. Lesion location precludes resection and the only current option available is radiotherapy. Patient age, duration of symptoms, histone subtype mutation etc. may helpl in prognostication but the disease remains incurable with a median overall survival of 9–12 months. Method This is a prospective observational study from a tertiary health care center in a low to middle-income country. We included patients with DIPG (radiological and/or histopathological H3K27M altered) from June 2018 to April 2023. Clinical, radiological, histology, and molecular features were reviewed and prognostic factors for 3 months, 6 months, and overall survival was analysed for all patients. Results We included 92 pediatric patients. The median age of our study population was 8.5 years. Median LPS was 80. Cranial nerve palsy was the most common presenting complaint. Hydrocephalus requiring CSF diversion was present in 38 patients (41.3%). Lesion biopsy was performed in 36 patients (39.1%) and exophytic component decompression was done in 11 patients (11.9%). Seven patients were lost to follow-up. Adjuvant therapy was received by 51 patients (51/85, 60%). Radiotherapy was the only significant prognostic indicator of 3 months, 6 months, and overall survival (HR: 0.39). The presence of necrosis on histopathology was also an indicator of poor prognosis (HR: 2.38). There were 7 long-term survivors in our study but we did not find any significant survival prognostic indicator amongst this group. Conclusion Conventional adjuvant therapy has not proven of much benefit. With the advancement in molecular understanding of the entity, there is an upsurge in the development of targeted therapy but with no promising results so far. In this study, we have attempted to explore the prognostic factors and unique challenges we face in a resource-limited setting against this disease.Keywords
This publication has 36 references indexed in Scilit:
- Pediatric diffuse intrinsic pontine glioma: where do we stand?Cancer and Metastasis Reviews, 2019
- Hypofractionated radiotherapy with temozolomide in diffuse intrinsic pontine gliomas: a randomized controlled trialJournal of Neuro-Oncology, 2019
- Role of Radiation Therapy in the Management of Diffuse Intrinsic Pontine Glioma: A Systematic ReviewAdvances in Radiation Oncology, 2019
- Recommendations for the organisation of care in paediatric radiation oncology across Europe: a SIOPE–ESTRO–PROS–CCI-Europe collaborative project in the framework of the JARCEuropean Journal of Cancer, 2019
- Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine GliomaCancer Cell, 2017
- Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypesActa Neuropathologica, 2015
- Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implicationsActa Neuropathologica, 2014
- K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomasActa Neuropathologica, 2012
- Prospective Evaluation of Radiotherapy With Concurrent and Adjuvant Temozolomide in Children With Newly Diagnosed Diffuse Intrinsic Pontine GliomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Management of pediatric pontine gliomasChild's Nervous System, 1991